Your browser is no longer supported. Please, upgrade your browser.
FBIOP Fortress Biotech, Inc. daily Stock Chart
Fortress Biotech, Inc.
Index- P/E- EPS (ttm)-1.59 Insider Own- Shs Outstand56.68M Perf Week0.00%
Market Cap1.12B Forward P/E- EPS next Y- Insider Trans- Shs Float33.54M Perf Month2.86%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter20.57%
Sales228.27M P/S4.90 EPS this Y- Inst Trans- Short Ratio- Perf Half Y7.92%
Book/sh0.67 P/B29.39 EPS next Y- ROA- Target Price- Perf Year-3.78%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range11.90 - 23.65 Perf YTD37.26%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-16.49% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low65.97% ATR0.54
Employees88 Current Ratio- Sales Q/Q35.80% Oper. Margin- RSI (14)56.51 Volatility1.47% 2.53%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.46 Prev Close19.66
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume3.34K Price19.75
Recom- SMA200.86% SMA506.56% SMA2005.43% Volume1,552 Change0.47%
Nov-09-18 08:50AM  Fortress Biotech (FBIO) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:47AM  Fortress Biotech: 3Q Earnings Snapshot Associated Press
Nov-01-18 11:28AM  Will Fortress Biotech (FBIO) Report Negative Earnings Next Week? What You Should Know Zacks -5.75%
Dec-05-17 02:44PM  Big apple-based biotechs new gene therapy subsidiary inks UNC licensing deals American City Business Journals
Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States. It also develops CK-301 for treating patients with non-small cell lung cancer (NSCLC); CK-101 for the treatment of patients with epidermal growth factor receptor mutation-positive NSCLC; and antibodies that target glucocorticoid-induced TNFR-related protein and carbonic anhydrase IX, as well as anti-cancer agents that inhibit bromodomain and extra-terminal proteins, and poly polymerase. In addition, the company develops CUTX-101 for treating Menkes disease; preclinical adeno-associated virus gene therapies for treating mucopolysaccharidosis type 1, dysferlinopathies, and corneal transplant rejection; Triplex, which is in Phase II clinical study for preventing and treating cytomegalovirus (CMV); and Pentamer, a vaccine drug candidate for preventing CMV. Further, it offers Targadox, a tablet for severe acne; Luxamend wound cream; Ceracade for treating dry skin conditions; Triderm for treating eczema, dermatitis, allergies, and rash; and chimeric antigen receptor and engineered T cell therapies across various cancers. Additionally, it provides retail brokerage and wealth management services to high net worth individual and institutional clients; investment banking, merger and acquisition, and advisory services to micro, small, and mid-cap high growth companies; trades in securities; liquidity services; and tax preparation, fixed insurance sales, and licensed mortgage brokerage services. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York..